KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Common Equity (2018 - 2025)

Castle Biosciences' Common Equity history spans 7 years, with the latest figure at $470.9 million for Q4 2025.

  • For Q4 2025, Common Equity rose 3.3% year-over-year to $470.9 million; the TTM value through Dec 2025 reached $470.9 million, up 3.3%, while the annual FY2025 figure was $470.9 million, 3.3% up from the prior year.
  • Common Equity for Q4 2025 was $470.9 million at Castle Biosciences, up from $467.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $470.9 million in Q4 2025 and bottomed at $378.8 million in Q2 2023.
  • The 5-year median for Common Equity is $413.8 million (2021), against an average of $419.3 million.
  • The largest annual shift saw Common Equity soared 376.05% in 2021 before it decreased 10.17% in 2023.
  • A 5-year view of Common Equity shows it stood at $411.7 million in 2021, then fell by 3.06% to $399.2 million in 2022, then dropped by 1.97% to $391.3 million in 2023, then grew by 16.5% to $455.8 million in 2024, then rose by 3.3% to $470.9 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Common Equity are $470.9 million (Q4 2025), $467.0 million (Q3 2025), and $455.4 million (Q2 2025).